BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized double blind, double dummy, placebo and active comparator controlled,
parallel design study that is being performed to assess the safety and efficacy of
risankizumab (BI 655066) to support registration for the treatment of moderate to severe
chronic plaque psoriasis in adult patients.